Back to Authors

Li, Zhuo

Mayo Clinic

Mayo Clinic in Florida

Citations 3

Multicenter Insights into Peritoneal Dialysis for Autosomal Dominant Polycystic Kidney Disease
Debeh, Fadi George Munairdjy , Ghanem, Ahmad , Rangarajan, Vineetha, Borghol, Abdul Hamid , Paul, Stefan , Alkhatib, Bassel , Nader, Nay , Antoun, Mikhail D., Hanna, Dana, Souvalian, Levon , Li, Zhuo, Gregory, Adriana , Kline, Timothy L. , Manohar, Sandhya , Porter, Ivan E. , Dillon, John , Kattah, Andrea G. , Khalillullah, Sayeed , Baker, Lyle W. , Trautman, Christopher L. , Aslam, Nabeel , Li, Zhuo , Munairdjy Debeh, Fadi George , Bou Antoun, Marie Therese , Kline, Timothy L , Mao, Michael A , Manohar, Sandhya , Porter, Ivan , Dillon, John J , Kattah, Andrea G , Khalillullah, Sayeed , Baker, Lyle Wesley , Trautman, Christopher L , Chebib, Fouad T , Aslam, Nabeel , Rangarajan, Vineetha, Nader, Nay , Hanna, Dana, Mao, Michael A. , Hickson, LaTonya J. , Chebib, Fouad T.

Kidney360 | July 7, 2025 | Volume: 6 | Issue: 11 | Pages: 1918-1927

10.34067/kid.0000000888 Get It

Key Points This study demonstrates that peritoneal dialysis is a safe and feasible option for patients with autosomal dominant polycystic kidney disease, even with high cystic organ volumes. Larger organ volumes, including height-adjusted cumulative kidney and liver volume, were not associated with increased peritoneal dialysis–related complications. Background Autosomal dominant polycystic kidney disease (ADPKD) is the most prevalent genetic kidney disorder and the fourth leading cause of kidney failure. Peritoneal dialysis (PD), preferred for its home-based convenience and cost-effectiveness, is often underutilized in ADPKD because of concerns over enlarged kidneys and heightened risk of complications. Methods This retrospective cohort study used data from the Mayo Clinic Polycystic Kidney Disease Database to evaluate individuals with ADPKD undergoing PD. We analyzed demographics, clinical parameters, and PD-related parameters. Complications were correlated with kidney and liver volumes derived from pre-kidney failure imaging. Results A total of 155 individuals with ADPKD on PD were included, of whom 45.1% were male. The mean age at PD initiation was 54.3±12.8 years, and the mean body mass index was 28.0±7.0 kg/m 2 . The median duration of PD was 24.3 months (interquartile range [IQR], 10.7–43.1), with 21.9% transitioning to hemodialysis. The most common complications were abdominal hernias (30.3%) and peritonitis (23.9%), with a peritonitis rate of 0.11 episodes per patient-year. Imaging analyses performed on a subset of 50 patients showed a median height-adjusted total kidney liver volume of 2731.9 ml/m (IQR, 2102.5–3131.1) and a median height-adjusted total kidney volume of 1303.5 ml/m (IQR, 733.1–1829.4). Kaplan–Meier analysis demonstrated no differences in complications rates on the basis of height-adjusted total kidney liver volume or height-adjusted total kidney volume (above versus below median values) or body mass index categories. Multivariate Cox regression analysis revealed that higher height-adjusted cumulative organ volume was associated with a lower risk of PD-related complications (hazard ratio=0.56, P = 0.026). Conclusions PD is a safe and feasible treatment option for patients with ADPKD, with no increased risk of PD-related complications associated with larger height-adjusted cumulative organ volumes. Infectious complication rates in this cohort were within International Society of Peritoneal Dialysis guideline thresholds, further supporting the safety of PD in this population.
Clinical Characteristics and Outcomes of Patients With COVID-19 Treated in Mayo Clinic’s Advanced Care at Home Program
Gothot, Rachel A., Haney, A.F., Li, Zhuo, Maita, Karla C. , Valles, Brittane T., Li, Zhuo , Haney, Amy A, Maniaci, Michael J. , Paulson, Margaret R. , Dumic, Igor , Haney, Amy A., Burger, Charles D.

Journal of Patient Safety | October 14, 2024 | Volume: 20 | Issue: 8 | Pages: 605-611

10.1097/pts.0000000000001286 Get It

Objectives Mayo Clinic’s hospital-at-home program, Advanced Care at Home (ACH), launched in 2020. While hospital-at-home literature reported safe and effective care for the general patient population and those with COVID, comparative outcomes between these two groups were unknown. The aim of this retrospective analysis was to compare the outcomes of COVID and non-COVID patients enrolled in ACH and evaluate if COVID patients can be safely treated in this setting. Methods Demographics, clinical characteristics, and safety outcomes were retrospectively analyzed to compare COVID and non-COVID patients discharged from ACH between November 2020 and May 2022. Patient characteristics analyzed included severity of illness (SOI) and risk of mortality (ROM), calculated using All Patient Refined Diagnosis Related Groups (APR-DRG). Hospitalization-specific variables included length of stay (LOS), escalation of care, and 30-day readmission rates. Results Of 1051 patients, 173 (16%) had COVID, and 878 (84%) were non-COVID patients. The average age in the COVID cohort was 66.6 (15.3) years, compared with 72.2 (14.0) in the non-COVID cohort. Extreme SOI was higher in the COVID group (43.3% versus 17.4%), as was extreme ROM (46.2% versus 16.2%), but LOS was shorter (5.7 versus 7 days). Escalation of care (7.5% in COVID cohort versus 8.4%) and 30-day readmission outcomes (9.2% for COVID patients versus 12.9%) were not statistically different between the groups. Conclusions Despite higher SOI and ROM, COVID patients had shorter LOS with outcomes that were not statistically different from non-COVID patients. COVID patients can be safely and efficiently cared for in ACH.
Impact of a Primary Inpatient Electrophysiology Service on Cardiovascular Implantable Electronic Device Infections in a Tertiary Care Hospital
Anderson, Brenda, Linderbaum, Jane A. , Ziel, Thomas De, Li, Zhuo, Cha, Yong‐Mei , Loomis, Erica, Espinosa, Raúl E. , Friedman, Paul A. , Greason, Kevin L. , Schiller, Henry J., Virk, Abinash , Wilson, Walter R., Steckelberg, James M., Tan, Eugene M. , Nagpal, Avish , DeSimone, Daniel C. , Sohail, M. Rizwan , Baddour, Larry M.

Open Forum Infectious Diseases | February 2, 2017 | Volume: 3 | Issue: suppl_1 | Pages: No page available

10.1093/ofid/ofw172.810 Get It